Galmed Pharma (GLMD) Misses Q4 EPS by 5c

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue
• Galmed's Colospan reports feasibility data on tissue assessment tool